Hedgehog signaling in basal cell carcinoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Basal cell carcinoma (BCC) is the most common skin cancer, sometimes exhibiting aggressive behavior.
• Genetic mutations in the hedgehog (Hh) pathway, particularly in PTCH and SMO genes, are frequently observed in BCC.
• The Hh pathway plays a critical role in BCC tumorigenesis, as evidenced by animal models.

Purpose of the Study:

• To review the role of the Hh pathway in BCC development and progression.
• To discuss the emerging therapeutic potential of Hh pathway inhibitors in BCC treatment.
• To explore the immunomodulatory effects of Hh pathway inhibitors and their implications for combination therapies.

Main Methods:

• Literature review of studies on BCC pathogenesis and Hh pathway signaling.
• Analysis of preclinical and clinical data on Hh pathway inhibitors.
• Examination of research on the interplay between Hh pathway inhibition and the tumor immune microenvironment.

Main Results:

• Hedgehog (Hh) pathway inhibitors are effective in suppressing BCC progression.
• Hh pathway inhibitors can stimulate acquired immune responses against BCC.
• The combination of Hh inhibitors with immune modifiers presents a novel therapeutic strategy.

Conclusions:

• Targeted therapies, including Hh pathway inhibitors, offer new avenues for BCC management.
• Hh pathway inhibitors possess immunomodulatory properties that can be leveraged for enhanced tumor control.
• Future clinical trials investigating combination therapies are warranted to optimize BCC treatment outcomes.